GMP Laboratory Data Integrity in 2026: Practical Strategies for FDA and MHRA Inspection Readiness

Description

GMP laboratory data integrity failures continue to remain a major inspection focus for FDA and MHRA investigators, particularly as laboratories become more digitally complex and increasingly dependent on hybrid workflows, computerized systems, audit trails, spreadsheets, and interconnected data environments. While most organizations have implemented standard procedural controls and ALCOA+ training, regulators continue to identify deeper operational weaknesses involving oversight effectiveness, analyst practices, access management, data review quality, and decision-making within laboratory operations.

In many cases, inspection concerns do not originate from a single missing record or isolated documentation issue. Instead, investigators assess whether laboratory behaviors, review practices, governance structures, and quality oversight collectively demonstrate reliable control over data generation, review, reporting, and escalation activities. Organizations often struggle to distinguish between controls that merely appear compliant and controls that truly reduce inspection vulnerability and operational risk.

_{WHY YOU SHOULD ATTEND:}

Many GMP laboratories already have data integrity procedures, audit trail reviews, training programs, and electronic systems in place. However, inspection findings related to laboratory oversight, analyst practices, access management, documentation reliability, and ineffective review activities continue to rise because regulators increasingly evaluate how organizations apply judgment, prioritize risk, and maintain meaningful operational control under real-world conditions.

Modern inspections are becoming more targeted, risk-focused, and signal-driven. Investigators are no longer assessing only whether procedures exist, but whether laboratory practices consistently demonstrate reliable execution, effective oversight, and credible decision-making across daily operations. In many organizations, hidden vulnerabilities develop gradually through routine practices that teams no longer recognize as inspection risks.

^{AREAS COVERED:}

• Current FDA and MHRA expectations for GMP laboratory data integrity
• How investigators interpret laboratory risk signals and oversight maturity
• Common operational practices that create hidden data integrity exposure
• Distinguishing procedural compliance from meaningful operational control
• Audit trail review strategies that provide real inspection value
• Managing spreadsheet, hybrid workflow, and access control vulnerabilities
• QA oversight, escalation decisions, and defensible risk prioritization
• Practical approaches for improving inspection readiness and laboratory governance

^{WHO SHOULD ATTEND:}

• Quality Assurance (QA)
• Quality Control (QC)
• Analytical Development Laboratories
• Regulatory Affairs
• Compliance and Validation Teams
• Manufacturing and Operations
• Laboratory Managers and Supervisors
• CMC and Technical Services Professionals

Course Director: Meredith Crabtree

Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.